[ET Net News Agency, 7 August 2020] Nomura cut its target price for Sino
Biopharmaceutical (01177) to HK$11.6 from HK$16.9 and maintained its "buy" rating.
The research house expects Sino Biopharm to report 0-5% top-line growth for the first
half of FY2020, driven by a recovery of the hospital market, further penetration of
Anlotinib, and continued sales ramp-up of FTM (first to market) generics approved in
2019-20.
Nomura expects the coming third national GPO (group purchasing organizations) to have a
neutral or even positive impact on Sino Biopharm. The company has 12 marketed or pipeline
products included in the third round national GPO, five of which were ANDA (abbreviated
new drug application) products approved in 2019-20. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
2.670 -0.010 (-0.373%) Others
07/08/2020 14:28
{I-bank focus}Nomura cuts Sino Biopharma (01177) to HK$11.6
| Remark: | Real time quote last updated: 25/04/2024 09:26 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |